TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04811040
Drug: Zinlirvimab
Normalized name: Zinlirvimab
DrugBank: Zinlirvimab (DB18867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT05367492
Drug: Double Blind Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For participants 16-17 years old, ≤ 55 kg:~* 0.5 mg once daily for 7 days, then~* 0.5 mg twice daily for 11 weeks~For participants 16-17 years old, \>55 kg:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks~For participants 18+ years old:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks
Study: NCT04789239
Drug: Sodium zirconium cyclosilicate
Normalized name: sodium zirconium cyclosilicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SZC is an approved drug in Sweden and subsidized for patients with chronic kidney disease in stages 3 to 5, with or without chronic heart failure, for whom treatment with Resonium is not suitable and for patients with chronic heart failure without con-comitant chronic kidney disease
Study: NCT04229979
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: injection
Study: NCT04229979
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: tablet
Study: NCT04229979
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injection
Study: NCT04229979
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: injection
Study: NCT05237388
Drug: Baricitinib
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One pill daily
Study: NCT06543628
Drug: Tadalafil 5mg
Normalized name: TADALAFIL 5MG TAB
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will take tadalafil once daily at a dose of 5 mg for 6 months.
Study: NCT05353374
Drug: Sodium Fusidate 2 % Topical Ointment
Normalized name: sodium fusidate 2 % Topical Ointment
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fusidate 2% topical ointment was applied twice daily on the wound after cauterization for 14 days.
Study: NCT05353374
Drug: Petrolatum ointment
Normalized name: GERI PROTECT Petrolatum Ointment
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Petrolatum ointment was applied twice daily on the wound after cauterization for 14 days.
Study: NCT05516589
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 260mg/m\^2 IV Q3W
Study: NCT05516589
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75mg/m\^2 IV Q3W
Study: NCT05516589
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 30mg PO QD
Study: NCT04817618
Drug: iptacopan
Normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iptacopan 200 mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
Study: NCT05583006
Drug: tenofovir alafenamide (TAF)
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TAF switch therapy in CHB patients who are unsatisfied to ETV therapy.
Study: NCT04949841
Drug: Delgocitinib
Normalized name: Delgocitinib
DrugBank: Delgocitinib (DB16133)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Delgocitinib cream 20 mg/g
Study: NCT05306379
Drug: Voclosporin
Normalized name: Voclosporin
DrugBank: Voclosporin (DB11693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dose 23.7 mg twice daily
Study: NCT06052618
Drug: Pacritinib
Normalized name: Pacritinib
DrugBank: Pacritinib (DB11697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pacritinib is administered orally as 200 mg twice daily for a total of 6, 28-day cycles
Study: NCT06323928
Drug: Lu AG09222
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu AG09222 will be administered using subcutaneous (SC) injection.
Study: NCT06084507
Drug: GST-HG171/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single oral dose of GST-HG171 300 mg (2 × 150 mg tablets)/ritonavir 100 mg under fed or fasted conditions at 0 hour on Day 1
Study: NCT06084507
Drug: ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single oral dose of ritonavir 100 mg at -12 hours prior to GST-HG171/ritonavir dosing, and ritonavir 100 mg will be dosed at 12 hours and 24 hours after GST-HG171/ritonavir dosing.
Study: NCT05544812
Drug: Sintilimab ，bevcizumab/cetuximab，XELOX
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients in this group had previously received the following treatment regimens:~Oxaliplatin :130 mg/m2, D1, Q3W; Capecitabine :1000mg/m2, bid q2w Sintilimab for injection :200mg, D1, Q3W Bevacizumab :7.5mg/kg, D1, Q3W or cetuximab :500 mg/m, D1, Q2W
Study: NCT05446168
Drug: tributyrin
Normalized name: Tributyrin
DrugBank: Tributyrin (DB12709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-biotic short chain fatty acid dietary supplement. Participants will take 500mg TID tributyrin supplement for 30 days +/- 7 days.
Study: NCT05737121
Drug: VNX001
DrugBank: NX001 (DB18099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VNX001 (alkalinized lidocaine HCl and heparin sodium)
Study: NCT05737121
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alkalinized lidocaine hydrochloride
Study: NCT06316427
Drug: Autologous CD7 CAR T-cell
Normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from patients.
Study: NCT06316427
Drug: Prior-HSCT donor-derived CD7 CAR T-cell
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from prior-HSCT donors.
Study: NCT06316427
Drug: New donor-derived CD7 CAR T-cell
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from new donors.
Study: NCT05011851
Drug: NNZ-2591
Normalized name: NNZ-2591
DrugBank: NNZ-2591 (DB15601)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.
Study: NCT05417789
Drug: Emactuzumab
Normalized name: Emactuzumab
DrugBank: Emactuzumab (DB14905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emactuzumab administered once every 2 weeks (q2w)
Study: NCT06043674
Drug: Glofitamab
Normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2:1 T-cell bispecific humanized monoclonal antibody, 2.5 mL or 10 mL single-use vial, via intravenous infusion per protocol.
Study: NCT06043674
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Humanized glycoengineered type II anti-CD20 monoclonal antibody, 50 mL single-use vial, via intravenous infusion per protocol.
Study: NCT06043674
Drug: Polatuzumab Vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Antibody-drug conjugate, 30 mg or 140 mg vial, via intravenous infusion per protocol.
Study: NCT06043674
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Humanized immunoglobulin monoclonal antibody, 840 mg/14 mL or 1200 mg/20 mL single-use vial, via intravenous infusion per protocol.
Study: NCT06043674
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For the treatment of Cytokine Release Syndrome. Recombinant, humanized, anti-human monoclonal antibody, 20 mg/mL single-dose vials, via intravenous infusion per protocol.
Study: NCT05406362
Drug: VAD044 Part I
Normalized name: VAD044
DrugBank: VAD-044 (DB17697)
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules to be taken once daily for 12 weeks
Study: NCT05227742
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral psilocybin once per week for 5 weeks.
Study: NCT05657925
Drug: ondansetron 8 mg
Normalized name: ondansetron 8 MG
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron 8 mg prn sublingually when awakening with nausea. as per the FDA label for ondansetron.
Study: NCT05688449
Drug: Bupivacaine-fentanyl
Normalized name: Bupivacaine-Fentanyl
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A 20 ml bolus of 2 mcg/ml fentanyl + 0.125% bupivacaine solution will be administered to the bupivacaine group via the epidural catheter, and 5ml/hour infusion will be started.
Study: NCT05688449
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A 20 ml bolus of saline will be administered to the saline group via the epidural catheter, and 5ml/hour infusion will be started.
Study: NCT06467942
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
DrugBank: Butylene glycol (DB14110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Chinese medicine group
Study: NCT06467942
Drug: Lactobacillus
Normalized name: lactobacillus
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Lactobacillus group
Study: NCT05974748
Drug: Sodium hypochlorite 5.25%
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The participants will be randomly divided into two groups using the sealed envelope method during the instrumentation process. The clinician will use the irrigation in accordance with the protocol. Between each instrument in group A, 3 ml of 5.25% sodium hypochlorite (NaOCl) will be used to irrigate each canal.
Study: NCT05730283
Drug: ORC-13661
Normalized name: ORC-13661
DrugBank: ORC-13661 (DB18903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intervention (30mg daily)
Study: NCT05730283
Drug: ORC-13661
Normalized name: ORC-13661
DrugBank: ORC-13661 (DB18903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose intervention (12mg daily)
Study: NCT06359379
Drug: Ropidoxuridine
Normalized name: Ropidoxuridine
DrugBank: Ropidoxuridine (DB06485)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropidoxuridine is administered daily, 5 days a week, for 7 weeks, starting one week prior to radiotherapy, and then concurrently with a standard 60 Gy radiotherapy, followed by a 4-week rest period.
Study: NCT06038981
Drug: Administration of 1g tranexamic acid intravenous bolus, after anesthesia was introduced
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The systemic use of tranexamic acid (TXA) has been shown to be effective in many types of surgery, reducing the incidence of post-operative bleeding and thereby reducing the rate of reoperation.~To evaluate if TXA systemic administration reduces postoperative blood loss in bariatric surgeries (sleeve gastrectomy operation)
Study: NCT00002121
Drug: Diethylhomospermine
Normalized name: Diethylhomospermine
DrugBank: Diethylhomospermine (DB13011)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05707936
Drug: Normal Saline Flush 20 ml
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal Saline Flush 20 ml
Study: NCT05707936
Drug: Normal Saline Flush 10 ml
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal Saline Flush 10 ml
Study: NCT05207670
Drug: Mosunetuzumab (Cohorts A-C)
Normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive SC mosunetuzumab for up to 17 cycles and for optional maintenance (Cohort A only)
Study: NCT05207670
Drug: Mosunetuzumab (Cohorts D-E)
Normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive SC mosunetuzumab for up to 34 cycles
Study: NCT05877820
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral tablet
Study: NCT05207670
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants can be treated with tocilizumab if they present with CRS after receiving mosunetuzumab
Study: NCT06482593
Drug: AH-Plus Epoxy Resin Sealer
Normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentsply AH Plus Root Canal Sealing Material is a two-component paste/paste root canal sealer based on epoxy-amine resin. The AH Plus sealer shows extremely low shrinkage making it a suitable choice of material to seal the root canal.
Study: NCT04539873
Drug: Colchicine 0.5 MG
Normalized name: colchicine 0.5 MG
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patientes in this arm will receive study medication colchicine 1,5 orally on the first day (initially two pills of 0,5 mg and 0.5 mg at 2 hours), followed by 0.5 mg every 12 hours on days 2 to 7, and continuing with 0.5 mg per day until completing 14 ± 1 days. The duration of treatment will be 14 ± 1 days, depending on the clinical judgment of the investigator.
Study: NCT00418249
Drug: AS101
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04899427
Drug: orelabrutinib
Normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orelabrutinib will be given as 150mg per day orally, until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
Study: NCT04899427
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab 200mg intravenous infusion d1, every 21 days for 1 cycle. The medicine will be given until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
Study: NCT04899427
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab 200mg intravenous infusion d1, every 21 days for 1 cycle. The medicine will be given until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
Study: NCT05441761
Drug: liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: Liposomal mitoxantrone hydrochloride (12 mg/m2, 16 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: gemcitabine (1000 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: dexamethasone (40 mg) will be administered on day 1-4 of each 21-day cycle.~Drug: cisplatin (75 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
Study: NCT05296733
Drug: BI 456906
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 456906
Study: NCT00002451
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002451
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00002451
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00002451
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06428682
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental group will receive TXA intraoperatively (15mg/kg IV, once at beginning of case then re dose at 4hrs if operation goes longer) at the time of their surgery.
Study: NCT03532958
Drug: BNZ-1
Normalized name: BNZ-1
DrugBank: EQ101 (DB17396)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEGylated peptide inhibitor of IL-2, IL-9, and IL-15
Study: NCT04940767
Drug: Isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin is a retinoic acid analogue (13-cis-retinoic acid) supplied as oral capsules. and was approved in the US for the treatment of severe acne vulgaris in 1982 under the brand name Accutane®.
Study: NCT06187922
Drug: Pregabalin 75mg
Normalized name: PREGABALIN 75MG CAP,UD
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Group pregabalin will receive cap pregabalin 75mg as premedication and will continue as B.D dose for 72 Hrs.
Study: NCT04811261
Drug: Intravenous Infusion of UCLSCs
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The first 3 subjects will be administered 50 x 10\^6 ULSCs reconstituted in PBS with 1% human serum albumin in a volume of 250 ml, and monitored for adverse events or toxicities, immediately following dosing, and again at 30 days.
Study: NCT05435209
Drug: Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
Normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gardasil
Study: NCT05088720
Drug: misoprostol 800 µg
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
Study: NCT05088720
Drug: misoprostol 400 µg
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: received misoprostol 400 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
Study: NCT06041490
Drug: multi-kinase inhibitors in combination with bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The eligible participants will start taking multi-kinase inhibitors between 4-8 weeks after liver transplantation. The choice of the specific multi-kinase inhibitor, including sorafenib, lenvatinib, or regorafenib, will be determined by the researchers based on factors such as the participant's tumor characteristics, liver function, physical condition, risk of side effects, economic status, and personal preference. The specific dosage and administration details can be found in the table provided. The maximum duration of multi-kinase inhibitor treatment will be 12 months or until any of the following conditions occur, whichever comes first: 1) The participant experiences intolerable toxic reactions that do not alleviate with dose adjustments, or 2) The participant has documented disease recurrence confirmed through imaging or withdraws from the study for other reasons.
Study: NCT00046878
Drug: O6-benzylguanine
Normalized name: O6-benzylguanine
DrugBank: 6-O-benzylguanine (DB11919)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00046878
Drug: carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05055128
Drug: X842 Dummy
Normalized name: Acaciae gummi
DrugBank: Acacia (DB10451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive matching placebo tablets for X842.
Study: NCT05055128
Drug: Lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive Lansoprazole capsule.
Study: NCT05055128
Drug: Lansoprazole Dummy
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive matching placebo capsules for Lansoprazole.
Study: NCT04483973
Drug: Ebselen
Normalized name: Ebselen
DrugBank: Ebselen (DB12610)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutathione peroxidase mimetic
Study: NCT05116007
Drug: AK112
Normalized name: IMMUNOGLOBULIN G1 (240-ALANINE,241-ALANINE), ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A) (HUMAN-MUS MUSCULUS MONOCLONAL AK112 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN PROGRAMMED CELL
DrugBank: Ivonescimab (DB18931)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT05116007
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
Study: NCT05116007
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4)
Study: NCT05634915
Drug: Individual ATG
Normalized name: equine ATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual dose of ATG: Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on population pharmacokinetic modeling). Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine A, mycophenolate mofetil, and low-dose methotrexate.
Study: NCT05634915
Drug: ATG
Normalized name: eATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG 10mg/kg: The total ATG dose was 10mg/kg. ATG was intravenously infused every day from day -5 to day -2. Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine A, mycophenolate mofetil, and low-dose methotrexate.
Study: NCT05208112
Drug: M6229
Normalized name: Metformin hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Continuous intravenous infusion of M6229, a low-anticoagulant fraction of heparin. Dose-escalation is based on a modified continual reassessment method (mCRM) including escalation with overdose control (EWOC).
Study: NCT04935359
Drug: NIS793
Normalized name: Anti-tgf-beta monoclonal antibody nis793
DrugBank: Nisevokitug (DB17561)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrate for solution infusion (Liquid in Vial)